Christine Simmon Talks Uptake Patterns: Biosimilars vs Generics
Christine Simmon talks about whether or not biosimilar uptake will happen as rapidly as it did for generics at the recent FDA/Federal Trade Commission workshop on anticompetitive practices.
Christine Simmon, JD, is the senior vice president of policy and strategic alliances for the Association for Accessible Medicines (AAM) and the executive director of AAM’s Biosimilars Council.
Transcript:
Will biosimilars be utilized to the same degree as generics?
To answer your question as to whether we will see the same level of uptake for biosimilars that we've seen in the generic realm, I think the jury's still out. These are more complex products. They are more costly to manufacture. They do require a higher level of investment and I think, most importantly, they are not, per se, interchangeable. I'm sure you know that the 90% dispensing rate that currently occurs in the United States for generic products is basically predicated on their automatic substitutability, which is, of course, a byproduct of being interchangeable. With biosimilars, the interchangeability that is unique to the United States is a separate designation that has to be achieved. So, I don't think we'll see [fast biosimilar uptake]. Certainly not as rapidly [as generics]. It's a longer-term play, and we'll have to wait and see.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Dr Fran Gregory Sizes Up the US Adalimumab Market: Will Biosimilars See Success?
September 17th 2023On this episode of Not So Different, Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, analyzes the adalimumab market so far in the United States and provides insight into how the market needs to adapt to accept these products and ensure lower drug costs for patients.
Dr Joseph Alvarnas Highlights the Current State of the Oncology Biosimilar Market
November 9th 2022Joseph Alvarnas, MD, vice president of government affairs at City of Hope and chief clinical adviser of AccessHope, explains what the recent FDA approvals of Stimufend and Vegzelma, 2 oncology biosimilars, says about the current state of the oncology biosimilar space.
Expert Opinion: What Factors Will Have the Greatest Impact on US Adoption of Humira Biosimilars?
April 12th 2022Jeffrey Casberg, vice president of pharmacy at IPD Analytics, weighs in on the factors he thinks will most affect market share among adalimumab biosimilars when they enter the US market in 2023.
